{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:08:09Z","timestamp":1790784489416,"version":"4.1.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"abstract":"<jats:p>This case report describes 2 patients with pemphigus and off-label teclistamab use.<\/jats:p>","DOI":"10.1001\/jamadermatol.2026.3051","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:31:14Z","timestamp":1790782274000},"source":"Crossref","is-referenced-by-count":0,"title":["BCMA-Targeted T-Cell Engager Therapy for Refractory Pemphigus"],"prefix":"10.1001","author":[{"given":"Moritz","family":"Ronicke","sequence":"first","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rothe","sequence":"additional","affiliation":[{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Rheumatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Hematooncology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Rheumatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Grieshaber-Bouyer","sequence":"additional","affiliation":[{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Erlangen, Germany"},{"name":"Department of Rheumatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"4","key":"dlo260014r1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jid.2021.09.013","article-title":"Temporal outcomes after rituximab therapy for pemphigus vulgaris.","volume":"142","author":"Tovanabutra","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"3","key":"dlo260014r2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"9","key":"dlo260014r3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease.","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"dlo260014r4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"dlo260014r5","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.jid.2017.05.032","article-title":"Pivotal role of lesional and perilesional T\/B lymphocytes in pemphigus pathogenesis.","volume":"137","author":"Yuan","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"10083","key":"dlo260014r6","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2854276\/jamadermatology_ronicke_2026_lo_260014_1789155008.56953.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:31:14Z","timestamp":1790782274000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2854276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":6,"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.3051","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}